共 36 条
[1]
Rajkumar S.V., Treatment of multiple myeloma, Nat. Rev. Clin. Oncol., 8, pp. 479-491, (2011)
[2]
Palumbo A., Anderson K., Multiple myeloma, N. Engl. J. Med., 364, pp. 1046-1060, (2011)
[3]
Rollig C., Knop S., Bornhauser M., Multiple myeloma, Lancet, 385, pp. 2197-2208, (2015)
[4]
Rajkumar S.V., Dimopoulos M.A., Palumbo A., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol., 15, 14, (2014)
[5]
Morgan G.J., Walker B.A., Davies F.E., The genetic architecture of multiple myeloma, Nat. Rev. Cancer, 12, pp. 335-348, (2012)
[6]
Wallington-Beddoe C.T., Sobieraj-Teague M., Kuss B.J., Pitson S.M., Resistance to proteasome inhibitors and other targeted therapies in myeloma, Br. J. Haematol., 182, pp. 11-28, (2018)
[7]
Michels T.C., Petersen K.E., Multiple myeloma: diagnosis and treatment, Am. Fam. Physician, 95, pp. 373-383, (2017)
[8]
Fisk H.A., Mattison C.P., Winey M., A field guide to the Mps1 family of protein kinases, Cell Cycle, 3, pp. 439-442, (2004)
[9]
Pachis S.T., Kops G.J.P.L., Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis, Open Biol, 8, (2018)
[10]
Tannous B.A., Kerami M., Van der Stoop P.M., Kwiatkowski N., Wang J., Zhou W., Kessler A.F., Lewandrowski G., Hiddingh L., Sol N., Lagerweij T., Wedekind L., Niers J.M., Barazas M., Nilsson R.J.A., Geerts D., De Witt Hamer P.C., Hagemann C., Vandertop W.P., Van Tellingen O., Noske D.P., Gray N.S., Wurdinger T., Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs, J. Natl. Cancer Inst., 105, pp. 1322-1331, (2013)